Evidence map›Paper›PMID 36447752›Full record

ArticleContrast media & molecular imaging2022

Detection of Bone Metastases by

Rui Tian, Qing Xie, Fei Yu, Changzhi Du, Xiaochen Yao, Shiming Zang, Chuan Zhang, Pengjun Zhang, Guoqiang Shao, Zhi Yang and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contrast media & molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Rui TianDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.ORCID 0000-0002-7023-0157
Qing XieKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing 100142, China.ORCID 0000-0003-1238-8500
Fei YuDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.ORCID 0000-0002-7269-2056
Changzhi DuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing 100142, China.ORCID 0000-0001-8580-1218
Xiaochen YaoDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.ORCID 0000-0001-7161-2870
Shiming ZangDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.ORCID 0000-0003-1398-3379
Chuan ZhangDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.ORCID 0000-0002-5584-0715
Pengjun ZhangDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.ORCID 0000-0002-8886-246X
Guoqiang ShaoDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.ORCID 0000-0002-3277-6933
Zhi YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing 100142, China.ORCID 0000-0003-2084-5193
Feng WangDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.ORCID 0000-0003-1089-3095
Jiangyuan YuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital and Institute, Beijing 100142, China.ORCID 0000-0002-6834-3080
Nanjing Medical University · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aimed to assess the efficacy of dual-tracer [ Methods: We retrospectively enrolled 74 GEP-NEN patients with BMs from two centers, who underwent dual-tracer PET/CT from January 2014 to March 2021. We compared and analyzed effectiveness of the dual PET/CT imaging techniques on the BMs, based on Results: The detection efficiencies of dual-tracer PET/CT imaging in patients with different pathologies showed discordant for detecting liver metastases and BMs in group neuroendocrine tumor (NET) G3, Conclusions:

Indexed as

Bone NeoplasmsGastrointestinal NeoplasmsNeuroendocrine TumorsOsteolysisFluorodeoxyglucose F18Gallium RadioisotopesHeterocyclic Compounds, 1-RingHumansKi-67 AntigenPositron Emission Tomography Computed TomographyReceptors, SomatostatinRetrospective Studies1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidFluorodeoxyglucose F18Gallium RadioisotopesHeterocyclic Compounds, 1-RingKi-67 AntigenReceptors, Somatostatin

Identifiers

PMID36447752
PMCPMC9663244
OpenAlexW4308587981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.